- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Demetri Discusses Regorafenib for GIST Patients
June 4th 2012, 8:56am
Dr. George Demetri, from Dana-Farber Cancer Institute, Discusses Regorafenib for Patients with GIST Trial Results.
Regorafenib Offers New Hope for Patients With Treatment-Resistant GIST
June 4th 2012, 6:15am
The oral multikinase inhibitor regorafenib reduced the risk of disease progression by 73% in patients with gastrointestinal stromal tumors who had exhausted all other treatment options.
Afatinib Prolongs PFS in Lung Cancer Trial
June 4th 2012, 6:00am
Afatinib markedly prolonged PFS compared with standard chemotherapy in patients with advanced lung adenocarcinomas that tested positive for EGFR mutations, particularly one of two common mutation types.
Bevacizumab Plus Second-Line Chemotherapy Extends Survival in Advanced Colorectal Cancer Patients
June 3rd 2012, 4:39pm
Bevacizumab plus chemotherapy as a second-line treatment for metastatic colorectal cancer improved survival among patients whose disease had progressed after first-line combination therapy with bevacizumab.
Dr. Blackwell Discusses the T-DM1 EMILIA Trial
June 3rd 2012, 9:20am
Dr. Kimberly Blackwell, from the Duke Cancer Institute, Discusses the T-DM1 EMILIA Trial
Dr. Rummel on Treanda Plus Rituxan in Indolent Lymphoma
June 3rd 2012, 8:11am
Dr. Mathias Rummel, from University Hospital Giessen in Germany, on Bendamustine Plus Rituximab in Indolent and Mantle Cell Lymphomas
Antibody Drug Conjugate T-DM1 Improves PFS in HER2-Positive Breast Cancer
June 3rd 2012, 6:02am
T-DM1 extended progression-free survival by 3.2 months in women with HER2-positive locally advanced or metastatic breast cancer.
Bendamustine Superiority in Lymphoma Regimen Confirmed
June 3rd 2012, 5:26am
Bendamustine should become the preferred chemotherapy standard of care in initial combination regimens for indolent lymphomas and mantle cell lymphoma.
With Continuous Hormonal Therapy, Certain Men With Prostate Cancer Get Marked Boost in Survival
June 3rd 2012, 5:00am
Patients with metastatic, hormone-sensitive prostate cancer and minimal disease spread experience a two-year boost in median survival when treated with continuous, rather than intermittent, hormonal therapy.
Dr. Pujade-Lauraine on the AURELIA Bevacizumab Trial
June 2nd 2012, 2:19pm
Dr. Eric Pujade-Lauraine, from Université de Paris Descartes, France, on the AURELIA Bevacizumab Trial for Platinum-Resistant Ovarian Cancer.
Dr. Topalian on the PD-1 Targeted Therapy BMS-936558
June 2nd 2012, 9:09am
Dr. Suzanne Topalian, from Johns Hopkins University School of Medicine, on the PD-1 Targeted Therapy BMS-936558
Avastin Delays Disease Progression in Platinum-Resistant Ovarian Cancer
June 2nd 2012, 6:27am
Combining bevacizumab with standard chemotherapy reduced the risk of disease progression by 52% in patients with platinum-resistant ovarian cancer.
Patients With Metastatic Kidney Cancer Prefer Pazopanib Over Sunitinib, Study Shows
June 2nd 2012, 6:21am
Study finds that more than two-thirds of patients with metastatic kidney cancer prefer pazopanib over another FDA-approved treatment, sunitinib.
Large Study of ALL Patients Finds Lower Survival in Adolescent and Young Adult Patients
June 2nd 2012, 5:59am
Adolescent and young adult patients between the ages of 16 and 30 had poorer outcomes when given the same treatment regimen as younger acute lymphoblastic leukemia patients.
PD-1 Immunotherapy Makes Strong Showing in Three Tumor Types
June 2nd 2012, 5:39am
An immunotherapy agent that targets the PD-1 pathway demonstrated response rates as high as 28% in an early-phase study involving patients with different tumor types.
Dr. Rotkowitz on BRAF/MEK Combination Side Effects
June 1st 2012, 4:01pm
Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, on Dabrafenib and Trametinib Combination Side Effects
Analysts, Companies Highlight Key ASCO Research
June 1st 2012, 5:00am
Pharmaceutical industry analysts and companies have been weighing in on their selections for the most noteworthy research to be presented during the 2012 ASCO Annual Meeting.
2012 ASCO Pre-Meeting Video Coverage
May 31st 2012, 2:10pm
American Society of Clinical Oncology (ASCO) 2012 Annual Meeting video highlights, from OncLive TV.
Advanced Coverage Recap: 2012 ASCO Annual Meeting
May 30th 2012, 1:51pm
On May 16, the ASCO highlighted the results of five ground-breaking studies in advance of its annual meeting held in Chicago from June 1-5, 2012.
Dr. Goy Highlights Research From the 2012 ASCO Meeting
May 30th 2012, 12:40pm
Dr. Andre Goy, from John Theurer Cancer Center, Highlights Research From the 2012 ASCO Meeting.